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Summary Biological response modifiers such as interleukin 2 (IL2) may be most effective in the setting of
minimal residual disease. In a phase I-II clinical trial, IL2 was administered to 10 patients in remission of
acute myeloid leukaemia and three with multiple myeloma 1-4 weeks after treatment with ablative
chemotherapy or chemotherapy and autologous bone marrow transplantation. The aim was to assess the
capacity of these patients to tolerate IL2 after intensive therapy and to determine whether regenerating
lymphocytes were capable of responding to IL2 with the generation of anti-leukaemic effector cells. Toxicity
was severe in two patients treated with escalating doses of IL2 and 19 subsequent infusions administered to II
patients on a fixed dose schedule for periods of 3-5 days were well tolerated. Major toxicity was confined to
hypotension (two courses) which responded rapidly to treatment cessation. No patients required intensive care
unit support. IL2 infusions produced no significant adverse effects on marrow regeneration; while there were
transient falls in platelet counts there were no episodes of clinical bleeding and neutrophil counts increased
from a mean of 1.1 pre-infusion to 2.5 x 109 1' during the infusion (P = 0.004). A significant biochemical
abnormality was hypokalaemia which responded rapidly to correction. Cells with activity against leukaemic
progenitor cells appeared in peripheral blood within 48 h of beginning treatment. We conclude that IL2 may
be used in minimal residual haematological malignancy, and by producing anti-neoplastic effector cells has the
potential, as yet unproven, to prolong disease-free survival of patients entering remission.
Despite the fact that a high proportion of patients with
malignant disease achieve remission after intensive chemo-
radiotherapy, the majority experience recurrence of their
disease and ultimately die. This applies particularly to acute
myeloid leukaemia, where long-term disease-free survival
with chemotherapy is around 25% despite current complete
remission rates of 70-75% (Champlin et al., 1985; Rees et
al., 1986). Relapse in these patients is likely to be due to the
presence of minimal residual malignancy during apparent
complete remission since cytogenetic study of leukaemic cells
at relapse shows the same pattern as at diagnosis in over
95% of cases (Garson et al., 1989). The risk of relapse in
AML is reduced after both autologous and allogeneic bone
marrow transplantation (BMT) (Gorin et al., 1986; Appel-
baum et al., 1988). The implication is that BMT is more
effective than chemotherapy alone in the elimination of
residual disease, perhaps by virtue of a graft versus
leukaemia (GvL) effect. One mechanism by which BMT may
produce a GvL effect and eliminate minimal residual disease
(MRD) may involve MHC-unrestricted activated killer (AK)
cells. These cells are present in the circulation of patients
following both autologous and allogeneic BMT, but are not
detected after chemotherapy alone (Reittie et al., 1989). They
may exert an anti-leukaemic effect either by direct cell-
mediated cytotoxicity or by the release of cytotoxic cytokines
such as TNF and gamma interferon.
Activated killing and cytokine release can be induced in
cells regenerating after chemotherapy alone by in vitro
incubation with interleukin 2 (IL2) (Adler et al., 1988) and
this cytokine augments activation still further after marrow
transplantation (Leger et al., 1987). If cytokine producing
AK cells are important in elimination of MRD then adminis-
tration of IL2 may reduce the risk of relapse after both
chemotherapy and marrow transplantation.
However, the timing of IL2 administration may be critical.
Soon after intensive conventional cytoreductive therapy
residual disease is at its nadir and likely to be most suscepti-
ble to the effects of biological response modifiers such as IL2.
Studies with other cytokines such as alpha interferon (Talpaz
et al., 1987; Mandelli et al., 1988), suggest that biological
response modifiers are most effective when given to patients
with early stage disease. In some cases, minimal residual
disease can be reduced to undetectable limits even though
identical treatment given to patients with more advanced
disease has negligible effects. The constraint on using IL2
soon after remission induction/BMT is that treatment with
IL2 alone is known to be associated with considerable tox-
icity (Rosenberg et al., 1987). Administration in close prox-
imity to the intensive chemo(radio)therapy required for AML
therapy and BMT conditioning may therefore be impossible
due to the combination of adverse effects.
To investigate the feasibility of combining intensive chemo-
radiotherapy with IL2 infusion, we have undertaken a phase
I clinical trial of IL2 in patients completing intensive
chemotherapy to induce remission of haematological malig-
nancy, or following marrow transplantation. We investigated
whether clinically tolerated doses of lL2 generated circulating
cells with anti-neoplastic activity. Finally we determined
whether the myelosuppressive effect of chemo-radiotherapy
would be exaggerated by IL2 to a degree which would neces-
sitate a compromise in standard cytotoxic therapy.
Patients, materials and methods
Patients
A total of 13 (9 male, 4 female) patients were studied and
details are shown in Tables I-III. Age ranged from 18 to 67
years with a median age of 36 years. Ten patients with acute
myeloid leukaemia (AML) and three with multiple myeloma
(MM) were included. To be eligible for entry into the study,
patients were required to have been treated with combination
chemotherapy plus or minus total body irradiation and
autologous BMT, before IL2 therapy. Eligibility criteria also
included a bone marrow aspirate demonstrating complete or
partial remission of haematological malignancy, normal renal
and hepatic function, and no prior treatment with biological
response modifiers or other investigational agents. Patients
were excluded from the study if they had any of the follow-
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ing: evidence ofcontinuing systemic or local infection, known
hypersensitivity to E. coli derived preparations, evidence of
cardio-respiratory decompensation or history of disabling
congestive cardiac failure or unstable angina. Hospital ethical
practices committee approval for the trial was given and
written informed consent was given by all patients before the
commencement of treatment.
Clinical and laboratory monitoring
All patients were monitored before treatment and then daily
during the course of the study by physical examination and
by measurement of pulse, blood pressure, temperature and
weight. Full blood count (using the Ortho ELT laser light
scatter system) with differential and full biochemical analysis
(including serum magnesium) were also undertaken daily.
Automated differential counts were confirmed by examining
May Grunewald Giemsa stained blood films by light micro-
scopy. All patients enrolled on the study had a pre-treatment
chest X-ray and electrocardiogram. Subsequent examinations
were performed as clinically indicated.
Cytotoxic chemotherapy and transplantation conditioning
Chemotherapy regimens were as follows: MACE (m-
amsacrine 100 mg m-2 i.v. x 5, cytosine arabinoside
100 mg m-2 x 5, etoposide 100 mg mi-2 day-' x 5), high dose
cytosine arabinoside (0.5-1.0 g m2 b.d. i.v. over 2 h x 5),
mitozantrone plus high dose cytosine arabinoside (mitozant-
rone 10 mg m-2 x 5, ara-c 0.5-O1.0g-2b.d. i.v. over 2 h x 5)
or high dose melphalan (melphalan 200 mg m-2) followed by
autologous marrow infusion. Patients with AML received
IL2 following one of the above chemotherapy regimens for
remission induction or consolidation. If undergoing
autologous bone marrow transplantation (in first or second
complete remission) they received cyclophosphamide
60 mg kg-' i.v. on days -4 and -3 of the transplant followed
by 750 cGy total body irradiation in a single fraction before
receiving high dose melphalan and autologous marrow
infusion.
Recombinant IL2
Recombinant IL2 cloned in E. coli with specific activity
between 1.7 and 3.2 x 106 mg' protein was provided by
Glaxo IMB, Geneva. One unit of this material is equivalent
to 1 unit of the National Institute of Biological Standards
reference preparation. Lyophilised material was reconstituted
in 46 ml sterile water for injection and 2 ml 10% serum
albumin added as a protein carrier. The drug was
administered in all but one case using a syringe pump via a
central venous Hickman catheter previously inserted for the
administration of cytotoxic agents, antibiotics or parenteral
nutrition. All patients received paracetomol 1 g 6-hourly and
chlorpheniramine 4 mg 6-hourly orally as fever prophylaxis
during the period of rIL2 administration. Patients also
received continous infusions of pethidine (doses
5-15 mg h-') during rIL2 administration in order to
minimise discomfort from associated febrile reactions.
Study design
Two initial patients (one following chemotherapy, one fol-
lowing autologous BMT) were treated with escalating doses
of rIL2 beginning 48 h after completion of chemotherapy or
marrow reinfusion. Doses were commenced at
50itg m-2day-' of protein, doubling every 48 h to maximum
tolerance. Infusions were given each day over a 6 h period. In
all subsequent courses, infusions were commenced only after
the recovering neutrophil count in the peripheral blood had
exceeded 0.5 x 109 1-'. Nineteen courses were given at a fixed
dose of rIL2 by daily 6 h infusion or by continuous infusion
for periods between 3 and 5 days. Dose escalation between
courses from 170 to 750 tLg m-2day-' was used to assess
clinical tolerance of rIL2.
Preparation ofmononuclear cells
Venous blood (60-100 ml) was drawn from patients daily or
on alternate days, beginning before the rIL2 infusion and
ending at day +2 to day +7 post-infusion. After centrifuga-
tion on Ficoll (Nycomed, Norway) and washing in
RPMI 1640 (Flow Lab.), cells were resuspended in RPMI
supplemented with Penicillin/Streptomycin (100 Uml-') and
10% heat inactivated fetal calf serum.
Inhibition ofclonogenicprogenitor growth
Cryopreserved leukaemic blast cells were thawed, washed
once in RPMI 1640 medium, resuspended in McCoy's
medium supplemented as previously described (Heslop et al.,
1988) and incubated overnight at 37°C in 5% CO2. Blasts
were incubated alone or with peripheral blood mononuclear
cells from patients receiving IL2, at a ratio of 1:3. Viability
was assessed after overnight incubation and blasts at a final
concentration of I05 ml-' were plated in 0.3% agar in 35 mm
Petri dishes. Triplicate cultures were performed. Recom-
binant human GM-CSF 1000pM and IL3 56 U (Glaxo IMB,
Geneva) were used as a source ofcolony stimulating activity.
Clusters, between 3 and 40 cells, and colonies, over 40 cells




Prolonged treatment Two patients were treated immediately
after completing cytotoxic chemotherapy or autologous
BMT. They developed severe toxicity requiring interruption
of IL2 treatment when a daily dose of 800ggm-2 had been
reached after 11 and 12 days of therapy respectively. Results
in these two patients are summarised in Table I. Both
patients developed dyspnoea and hypotension. Side effects
resolved within 6 h in the first case but the second patient
developed a persistent fever despite cessation of IL2. An
interstitial pneumonitis developed and he deteriorated and
died 2 days later.
Short course infusions Subsequently, 19 courses of IL2, 10
following chemotherapy alone and nine after BMT, were
given by daily i.v. infusion over either 6 or 24h, begining
only when the neutrophil count had reached 0.5 x i091-'.
Infusions continued for periods of between 3 and 5 days.
Daily doses remained constant throughout each course but
escalated between courses from 170 to 750 lig m-2day-'.
Toxicity in this group is summarised in Tables II and III.
Patient tolerance was good despite the frequent occurrence of
fever and nausea. Interruption of infusion was required dur-
ing three courses, twice due to hypotension and on one
occasion because of chest pain unassociated with clinical,
ECG or cardiac enzyme changes. In both cases of hypoten-
sion, blood pressure fell on the fifth day of infusion but
returned to normal in under 6 h following treatment with i.v.
fluids and, in one case transient inotropic support.
Haematological effects A modest but consistent drop in
haemoglobin level was seen in patients treated with rIL2
(Table IV). Investigative venesection accounts for only part
of this effect, which occurred at a rate of up to
0.5 gdl-' day '. Mean Hb fell from 11.7 to 10.3 g dl- dur-
ing infusion. Further falls were prevented by red cell trans-
fusion to maintain a Hb of over 10.0 g dl-' in all patients.
Total neutrophil count rose during IL2 infusion in 13 of 19
courses and fell or remained stable in six others. Mean value
increased from 1.1 x 109 1-' pre-treatment to 2.5 x 1091-
during infusion (P = 0.004), before falling to 1.6 x 1091'
48 h after infusion had finished (Table IV). In patients in
whom neutrophil counts fell during infusion, recovery to
pre-treatment levels was seen within 48-72 h of stopping IL2612 D.J. GOTTLIEB et al.
Table I Toxicity in two patients receiving IL2 in escalating dosesa
Total duration
Patient of IL2 Total dose IL2
Patient number age/sex Disease Prior treatment (days) (g mr-2) Adverse effects












aPatients received IL2 by daily infusions over 6h. bInfusion interrupted because of toxicity.
Table II Toxicity associated with 10 courses of IL2 given by short course fixed-dose infusion following cytotoxic chemotherapy
Total duration Daily dose
of IL2 IL2 Total dose IL2
Patient number Age/sex Disease Prior treatment (days) (sgm-2) (Lg m-2) Adverse effects
3 20M AML M3 HD Ara-C 3 160 480 fever
HD Ara-C 3 320 960 fever
4 33M AML M4 HD Ara-C 3 175 525 fever
HD Ara-C 3 350 1050 fever
nausea
5 45M AML M3 Mito/Ara-C 3 315 945 fever
nausea
Mito/Ara-C 3 580 1740 fever
nausea




6 30M AML M4 Mito/HD Ara-C 5a 600 2500 fever, rigors
nausea, vomiting,
hypotension
7 18M AML M2 MACE 5 630 3150 fever
nausea
MACE 5 630 3150 fever
nausea
skin rash
AML, acute myeloid leukaemia; MM, multiple myeloma; HD Ara-C, high dose cytosine arabinoside; Mito/Ara-C, mitozantrone
plus cytosine arabinoside. aCourse interrupted because of toxicity.
Table III Toxicity associated with nine courses of IL2 given by short course fixed-dose infusion following bone marrow
transplantation
Total duration Daily dose
of IL2 IL2 Total dose IL2
Patient number Age/sex Disease Prior treatment (days) (jgm-2) (Ag m 2) Adverse effects
8 58M MM Autologous BMT 3 160 480 fever
nausea
skin rash





9 29F AML M6 Autologous BMT 3 195 585 fever, rigors
myalgia
Autologous BMT 2a 390 600 fever, rigors
myalgia
chest pain
10 33F AML M7 Autologous BMT 4 480 1920 fever
myalgia
nausea





12 55F MM Autologous BMT 5 600 3000 fever
nausea, vomiting
peripheral oedema
Autologous BMT 5 600 3000 fever
nausea, vomiting
peripheral oedema




AML, acute myeloid leukaemia; MM, multiple myeloma. aCourse interrupted because of toxicity.IL2 IN MINIMAL RESIDUAL DISEASE 613
infusion. Overall, total eosinophil count was not significantly
changed (Table IV), although in one patient eosinophil count
increased from 1.2 to 3.0 and 4.6 x I09 I` before, during and
after IL2 respectively.
Table IV Haematology parameters
Pre During infusion After infusion
Hb (g/dl) 11.7 0.3 10.3 ± 0.2a
(P = 0.001)
neutrophil count 1.1 0.1 2.5 ± 0.5 1.6 0.3
( x 1091-1) (P = 0.004) (P = 0.041)
eosinophil count 0.09 ± 0.07 0.30 ± 0.17 0.75 ± 0.44
( x 1091-'1) (n.s.) (n.s.)
PB lymphocyte 2.1 ± 0.4 0.7 ± 0.1 8.1 ± 3.4
count ( x 1091-') (P=0.004) (P=0.064)
Platelets 107 16 79 ± 14 83 ± 20
(x 1091-) (P = 0.002) (n.s.)
Mean values with standard error for Hb, neutrophil count,
eosinophil count, peripheral blood lymphocyte count and platelet
count before, during and 48-72 h after completion of IL2 infusion.
Degree of statistically significant difference from pre-treatment level
is shown in parenthesis. aHb levels during infusion were the lowest
noted, before blood transfusion, if given.
Platelet count remained stable during the first 3 days of
IL2 infusion, but a significant fall was noted towards the end
of 5 day courses. Mean pre-treatment value was 107 x 109 1`
falling to 79 x 109 1` during infusion (P = 0.002) (Table IV).
Counts had returned to pre-treatment levels within 5 days of
completing infusion.
A rapid fall in peripheral blood lymphocyte (PBL) count
was noted in all patients within 24 h of commencing infusion
(Table IV). PBL count fell from 2.1 to 0.7 x 1091-1, but this
was followed by a rebound lymphocytosis, mean
8.1 x 1091-1, peaking at 48 h after IL2 was stopped.
Biochemical effects. Consistent falls were noted in serum
sodium, potassium, calcium phosphate and magnesium dur-
ing the period of rIL2 infusion (Table V). Hyponatraemia
developed progressively after the first 24-48 h of infusion
but did not require treatment in any case. In contrast,
hypokalaemia developing over the same time period required
intravenous K+ supplementation. Hypocalcaemia was seen
usually associated with falls in serum albumin (lowest level
1.51 mmol 1' with albumin 25 g 1'). Hypomagnesaemia was
at times severe (lowest Mg level 0.43 mmol 1`), particularly
when infusions of over 3 days were given, but resolved
quickly after stopping treatment. No calcium or magnesium
supplements were given to any of the patients during the
study.
Mild and transient abnormalities of hepatic and renal
function were found during a minority of IL2 infusions.
Significant increases were noted only in serum bilirubin and
creatinine in the treatment group as whole (Table V).
Although two infusions were associated with asymptomatic
WHO grade 3 increases in aspartate transaminase levels,
these and other changes in hepatic and renal function
resolved within 3-5 days of cessation of IL2.
Inhibition ofleukaemic cluster/colony growth
To discover whether the IL2 infusion modified anti-
leukaemic effector function, we studied the inhibition of
leukaemic colony growth by patient PBM. When patient
mononuclear cells taken before IL2 infusion were added to
cryopreserved allogeneic myeloid leukaemic blast cells at a
ratio of 3 to 1 overnight, subsequent culture produced less
than 10% inhibition of blast cluster and colony growth (see
Figure 1). Patient PBLs taken during IL2 infusion inhibited
clusters by a mean of 46.5% ( ± s.e.m. 11.3, n = 8) and col-
onies by a mean of 70.1% (s.e.m. 15.3, n = 8). Clusters were
reduced from a mean of 204.2 ± 46.5 to 67.6 ± 18 and col-
onies from 47 ± 11.6 to 8.7 ± 3.0 (P = 0.004 and <0.001
respectively).
Discussion
Previous studies of the anti-neoplastic effects of IL2 have
been undertaken in patients with bulk disease (Lotze et al.,
1986; West et al., 1987). We have given IL2 to patients
induced into a state of minimal residual disease by prior
high-dose chemotherapy alone or chemotherapy and
radiotherapy followed by autologous BMT. Patients were
treated shortly after chemo-radiotherapy, because at the
nadir of tumour load biological response modifiers may have
their greatest effect on residual malignancy.
Our intention was to use IL2 to induce AK cell function
which is not present after chemotherapy alone, or to intensify
AK cell function occurring spontaneously after BMT. By
inducing or increasing a state of activated killing, this
strategy aims to reduce the risk of relapse and improve
disease-free survival in patients entering remission. The con-
cern about such usage is that heavily pre-treated patients
may not tolerate IL2. Here, we have investigated the clinical
feasibility of this approach by administering IL2 to patients
shortly after intensive cytoreductive therapy for AML and
MM. These patients were chosen for three reasons. First,
they receive intensive combination chemotherapy or BMT,
and are thus considered to have received maximum tolerated
chemo-radiotherapy with severe potential toxicity. Secondly,
although they frequently achieve remission, the majority of
patients ultimately relapse, so that minimal residual disease
must generally be present. Finally, malignant cells in both
AML and MM are sensitive to lysis by activated killer cells
and the cytokines they produce (Oshimi et al., 1986;
Shimagaki et al., 1988).
Toxicity was a major problem in two patients treated for
extended periods, early after chemo-radiotherapy. In one
patient respiratory problems progressed to fatal interstitial
pneumonitis associated with intercurrent infection. Pul-
monary toxicity is a recognised complication of IL2 therapy
alone (Rosenberg et al., 1987), but may have been exacer-
bated by the predisposing effects of prior cytotoxic
chemotherapy and/or total body irradiation. All subsequent
courses were restricted to 5 days, and infusion was delayed
until the recovering neutrophil count had reached
0.5 x 1091-'. Pulmonary toxicity during these infusions was
limited to the development of a transient localised abnor-
Table V Biochemical parameters
Normal
range Pre During infusion P value
Sodium (135- 145 mmol1') 137.9 ± 0.8 133.4 ± 0.8 0.001
Potassium (3.5-5.0 mmol1') 3.8 ± 0.1 3.3 ± 0.1 0.009
Calcium (2.10-2.60mmol1-') 2.41 ± 0.03 2.14± 0.05 0.001
Magnesium (0.70- 1.00 mmol 1 ') 0.77 ± 0.02 0.58 ± 0.03 0.001
Bilirubin (5-17JLmollI') 10.9± 1.9 19.8 ±4.4 0.025
Alkaline phosphatase (5-40 U 1-') 122.4 15.4 188.6 36.1 0.080
Aspartate transaminase (35-130 U 1-') 42.0 5.5 59.5 16.2 0.313
Creatinine (60-120 lmol I-') 83.4 4.7 102.7 5.5 0.017
Mean values for extreme of serum sodium, potassium, calcium, magnesium, creatinine and
liver function tests before and during infusions of IL2, with standard error. Degree of statistical














Figure 1 Inhibition of leukaemia clusters and colonies by lym-
phocytes from patients before (E) and during (-) IL2 infusion.
Leukaemic blast cells were cultured as described in Methods and
percentage inhibition was calculated as:
number of colonies/clusters with lymphocytes
x 100 100-x10
number of colonies/clusters with blast cells alone
Phenotyping ofcolonies/clusters confirmed that the culture condi-
tions used induced no lymphoid colony growth. Results shown
are mean of triplicates.
mality on chest X-ray in one patient. Hypotension, recently
demonstrated to be due to reduced systemic resistance
(Gaynor et al., 1988), was the only other serious adverse
effect and responded rapidly to cessation of infusion, i.v.
colloid solutions and, on one occasion, inotropic support
with dopamine. Fever beginning on the second or third day
of infusion was found consistently, but in otherwise well
patients we did not initiate treatment with i.v. antibiotics.
The symptoms of fever and nausea were generally well cont-
rolled with standard antipyretic and antiemetic medication,
so that patient tolerance of short course infusions was good.
All adverse effects either completely resolved or considerably
improved within hours of cessation of infusion. All patients
in this group were nursed on a general haematology ward
and none required intensive care unit admission, so that this
type of treatment is within the scope of any unit capable of
administering combination chemotherapy.
Although in vitro data suggested that IL2 could potentially
exaggerate the myelosuppressive effect of conventional
cytotoxic agents (Heslop et al., 1988), in fact IL2 infusion
significantly increased neutrophil counts. When 1L2 infusion
was discontinued, the neutrophil count fell, indicating that
the rise was IL2 dependent and did not simply represent the
continuing recovery of a regenerating marrow. Although the
mechanism for this rise in WBC is unclear, our preliminary
data suggest that IL2 induces haemopoietic growth factors
such as GM-CSF and IL4. Nonetheless, interleukin 2 does
produce a decline in circulating platelet counts and a tran-
sient thrombocytopenia was observed towards the end of the
infusion course. Care may be required if IL2 is to be used as
an adjunct to regimens with prolonged suppressive effects on
megakarvocyte recovery.
After intensive chemotherapy/BMT, even short course IL2
administration produces falls in serum electrolytes including
sodium, potassium, calcium and magnesium. Hypokalaemia
required supplementation, but attention needs to be paid to
all electrolyte abnormalities as IL2 has been reported to be
associated with cardiac arrhythmias and neurological dys-
function (Rosenberg et al., 1987). The mechanism of these
abnormalities is unclear although a renal tubular effect may
be responsible in view of the fact that this is a known site of
IL2 metabolism (Donohue & Rosenberg, 1983).
As this study was undertaken in patients with minimal
residual disease, efficacy data have been based on a study of
the anti-leukaemic activity of cells from patient peripheral
blood. Activity substantially increased and cells capable of
inhibiting clonogenic leukaemic progenitor cells were
generated during IL2 treatment.
Our results show that IL2 can be safely administered to
patients who have recently received chemo-radiotherapy to
induce disease remission, as long as adequate attention is
paid to cytokine dose, duration of administration and patient
management. We have been able to demonstrate in vitro
anti-leukaemic affects induced by IL2 given in a dose that
was clinically acceptable and did not compromise conven-
tional cytotoxic treatment by exaggerating myelosuppression.
Larger scale studies with long follow-up will be necessary to
determine whether this inhibition will translate into im-
provements in remission duration or cure.
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